Immunotherapy and Vaccines
Stanley J. Cryz Jr.,
Marta Granstrom,
Bruno Gottstein,
Luc Perrin,
Alan Cross,
James Larrick,
Stanley J. Cryz Jr.
Swiss Serum and Vaccine Institute Berne, Switzerland
Search for more papers by this authorMarta Granstrom
Departments of Clinical Microbiology and of Vaccine Production, National Bacteriological Laboratory, Karolinska Hospital, Stockholm, Sweden
Search for more papers by this authorBruno Gottstein
Institut für Parasitologie, Universität Zürich, Zürich, Switzerland
Search for more papers by this authorLuc Perrin
Division d'Hematologie, Hôpital Cantonal Universitaire, Genève, Switzerland
Search for more papers by this authorAlan Cross
Department of Bacterial Diseases, Walter Reed Army Institute of Research, Washington D.C. 20307–5100, United States
Search for more papers by this authorJames Larrick
Genelabs Incorporated, Redwood City, California, United States
Search for more papers by this authorStanley J. Cryz Jr.,
Marta Granstrom,
Bruno Gottstein,
Luc Perrin,
Alan Cross,
James Larrick,
Stanley J. Cryz Jr.
Swiss Serum and Vaccine Institute Berne, Switzerland
Search for more papers by this authorMarta Granstrom
Departments of Clinical Microbiology and of Vaccine Production, National Bacteriological Laboratory, Karolinska Hospital, Stockholm, Sweden
Search for more papers by this authorBruno Gottstein
Institut für Parasitologie, Universität Zürich, Zürich, Switzerland
Search for more papers by this authorLuc Perrin
Division d'Hematologie, Hôpital Cantonal Universitaire, Genève, Switzerland
Search for more papers by this authorAlan Cross
Department of Bacterial Diseases, Walter Reed Army Institute of Research, Washington D.C. 20307–5100, United States
Search for more papers by this authorJames Larrick
Genelabs Incorporated, Redwood City, California, United States
Search for more papers by this authorFirst published: 15 June 2000
Abstract
The article contains sections titled:
1. |
Introduction |
1.1. |
Historical Aspects |
1.2. |
Principles and Definitions |
1.2.1. |
Antigens |
1.2.2. |
Antibodies |
1.2.3. |
Immune Response |
1.2.4. |
Active Immunization |
1.2.5. |
Passive Immunization |
1.2.6. |
Genetic Engineering |
2. |
Bacterial Vaccines |
2.1. |
Diphtheria Vaccine |
2.2. |
Tetanus Vaccine |
2.3. |
Pertussis Vaccine |
2.4. |
Typhoid Fever Vaccine |
2.5. |
Streptococcus pneumoniae Vaccine |
2.6. |
Shigella Vaccines |
2.7. |
CholeraVaccine |
2.8. |
Vaccines Against Nosocomial Pathogenes |
2.9. |
Meningococcal Meningitis Vaccine |
2.10. |
Tuberculosis Vaccine |
2.11. |
Escherichia coli Vaccines |
2.12. |
Neisseria gonorrhoeae Vaccine |
2.13. |
Hemophilus influenzae Type b Vaccines |
3. |
Viral vaccines |
3.1. |
Measles Vaccine |
3.2. |
Mumps Vaccine |
3.3. |
Rubella Vaccine |
3.4. |
Combined Measles - Mumps - RubellaVaccine |
3.5. |
Polio vaccine |
3.6. |
Hepatitis b Vaccine |
3.7. |
Rabies Vaccine |
3.8. |
Influenza Vaccine |
3.9. |
Varicella Vaccine |
3.10. |
Yellow Fever Vaccine |
3.11. |
Tick-Borne Encephalitis Vaccine |
3.12. |
Japanese Encephalitis Vaccine |
3.13. |
Smallpox Vaccine |
3.14. |
Rift Valley Fever Vaccine |
4. |
Vaccines against Parasites |
4.1. |
Vaccines against Helminths |
4.1.1. |
Vaccines against Schistosoma |
4.1.2. |
Vaccines against Nematodes |
4.1.2.1. |
Gastrointestinal Nematodes |
4.1.2.2. |
Tissue-Invading Nematodes (Filariidae) |
4.1.3. |
Vaccines against Cestodes |
4.2. |
Malaria Vaccine |
4.2.1. |
Strategy for Malaria Vaccine Development |
4.2.2. |
Sporozoite Vaccines |
4.2.3. |
Asexual Blood Stage Vaccine |
4.2.3.1. |
Merozoite Surface Antigens |
4.2.3.2. |
Rhoptry antigens |
4.2.3.3. |
Antigens Associated with the Membrane of Infected Erythrocytes |
4.2.3.4. |
Other Proteins and Synthetic Peptides |
4.2.4. |
Sexual Stages-Transmission Blocking Immunity |
5. |
Immunotherapy |
5.1. |
Gamma Globulin Preparations |
5.1.1. |
Standard Immune Serum Globulin |
5.1.2. |
Immunoglobulin for Intravenous Use |
5.1.3. |
Hyperimmune Globulins and Antitoxins |
5.1.4. |
Production Requirements |
5.2. |
Prophylaxis with Immune Serum Globulin |
5.3. |
Prophylaxis with Hyperimmune Globulins |
5.4. |
Therapy with Immune Serum Globulin |
5.5. |
Prophylaxis and Therapy with Intravenous Immunoglobulin (IVIG) |
5.5.1. |
Viral Infection |
5.5.2. |
Bacterial Infection |
5.5.3. |
Noninfectious Diseases |
5.5.3.1. |
Therapeutic Effect of IVIG |
5.5.3.2. |
Mechanism of Action |
5.6. |
Prophylaxis and Therapy with Plasma and Other Blood Products |
5.7. |
Adverse Effects of Gamma Globulin Preparations |
5.8. |
Future Prospects |
6. |
Immunotherapeutic Uses of Monoclonal Antibodies |
6.1. |
Introduction |
6.2. |
Bacterial Targets |
6.3. |
Viral and Chlamydial targets |
6.4. |
Parasite Targets |
References
- 1 I. Roitt: Essential Immunology, 5th ed., Blackwell Scientific Publications, Oxford, United Kingdom 1984.
- 2 B. D. Davis, R. Dubecco, H. N. Eisen, H. S. Ginsberg: Microbiology: Including Immunology and Molecular Genetics, 3rd ed., Harper and Row, Hagerstown, MD, 1980.
- 3 R. H. Schwartz, A. Yano, W. E. Paul: “Interaction between antigen-presenting cells and primed T-lymphocytes,” Immunol. Rev. 40 (1978) 153.
- 4 W. Stroler, L. A. Hanson, K. W. Sell (eds.): Recent Advances in Mucosal Immunity, Raven Press, New York 1982.
- 5 T. Yamamura, T. Tada: Progress in Immunology V, Academic Press, Tokyo 1984.
- 6 J. B. Robbins, J. C. Hill, J. C. Sadoff (eds.): Bacterial Vaccines, Seminars in Infectious Disease, vol. IV, Thieme-Stratton, New York 1982.
- 7 U. E. Nydegger (ed.): Immunotherapy, A Guide to Immunoglobulin Prophylaxis and Therapy, Academic Press, London 1981.
- 8 R. E. Black, M. M. Levine, M. L. Clements, G. Losonsky et al.: “Prevention of shigellosis by a Salmonella typhi – Shigella sonnei bivalent vaccine,” J. Infect. Dis. 155 (1987) 1260 – 1265.
- 9 M. M. Levine, J. B. Kaper, D. Herrington, J. Ketley et al.: “Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR,” Lancet 2 (1988) 467 – 470.
- 10 R. J. Collier: “Diphtheria toxin: mode of action and structure,” Bacteriol. Rev. 39 (1975) 54 – 85.
- 11
A. M. Pappenheimer, Jr., in
R. Germanier (ed.):
Diphtheria,
Bacterial Vaccines,
Academic Press, Orlando,
FL
1984,
pp. 1 – 36.
10.1016/B978-0-12-280880-7.50006-7 Google Scholar
- 12 F. Audibert et al.: “Active antitoxic immunization by a diphtheria toxin synthetic oligopeptide,” Nature (London) 289 (1981) 593 – 594.
- 13 T. Uchida, D. M. Gill, A. M. Pappenheimer, Jr.: “Mutation in the structural gene for diphtheria toxin carried by temperate phage β,” Nature (London) 283 (1971) 8 – 11.
- 14 L. Greenfield, H. L. Dovey, F. C. Lawyer, D. H. Gelfand: “High level expression of diphtheria toxin peptides in Escherichia coli,” Bio/Technology 4 (1986) 1006 – 1011.
- 15
B. Bizzinin in
R. Germanier (ed.):
Tetanus,
Bacterial Vaccines,
Academic Press, Orlando,
FL
1984,
pp. 37 – 68.
10.1016/B978-0-12-280880-7.50007-9 Google Scholar
- 16 M. C. Hardegree et al.: Titration of tetanus toxoids in international units; relationship to antitoxin responses of rhesus monkeys, 6th Proc. Int. Conf. Tetanus 1981, 1982, pp. 409 – 423.
- 17 M. Huet: La standardisation des vaccins tetaniques, 6th Proc. Int. Conf. Tetanus 1981, 1982 pp. 425 – 433.
- 18 K. W. Newell, A. Dueñas-Lehmann, D. R. Leblanc, N. Garces-Osorio: “The use of toxoid for the prevention of tetanus neonatorum; final report of a double-blind controlled field trial,” Bull. W.H.O. 35 (1966) 863 – 871.
- 19 N. Guerin, C. Fillastre: Vaccin D.T.C. Polan, 6th Proc. Int. Conf. Tetanus 1981, 1982, pp. 477 – 479.
- 20 M. Pittman: “Pertussis toxin; the cause of the harmful effects and prolonged immunity of whooping cough,“ Rev. Infect. Dis. 1 (1979) 401 – 412.
- 21
C. R. Manclark,
J. L. Cowell in
R. Germanier (ed.):
Pertussis,
Bacterial Vaccines,
Academic Press,
Orlando, FL
1984,
pp. 69 – 106.
10.1016/B978-0-12-280880-7.50008-0 Google Scholar
- 22 T. Madsen: “Vaccination against whooping cough,” JAMA J. Am. Med. Assoc. 101 (1933) 187 – 188.
- 23 C. L. Cody et al.: “Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children,” Pediatrics 68 (1981) 650 – 660.
- 24 R. Aldersdale et al.: Whooping Cough. Reports from the Committee on Safety of Medicines and the Joint Committee on Vaccination and Immunization, vol. 4, H. M. Stationary Office, London, England 1981, pp. 79 – 169.
- 25 M. Oda, J. L. Cowell, D. G. Burstyn, R. Manclark: “Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice,” J. Infect. Dis. 150 (1984) 823 – 833.
- 26 Ad Hoc Group for the study of Pertussis Vaccines: “Placebo controlled trial of two acellular pertussis vaccines in Sweden—protective efficacy and adresse events.” Lancet 1 (1988) 955 – 960.
- 27 C. S. Chuttani et al.: “Controlled field trial of a high-dose oral killed typhoid vaccine in India,” Bull. W.H.O. 55 (1977) 643 – 644.
- 28 M. Reitman: “Infectivity and antigenicity of streptomycin-dependent Salmonella typhosa,” J. Infect. Dis. 117 (1967) 101 – 107.
- 29 R. Germanier, E. Fürer: “Isolation and characterization of gal ε mutant Ty 21 a of Salmonella typhi; a candidate strain for a live, oral typhoid vaccine,” J. Infect. Dis. 131 (1975) 553 – 558.
- 30 R. H. Gilman, R. B. Hornick, W. E. Woodward, H. L. Dupont et al.: “Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a live oral vaccine,” J. Infect. Dis. 136 (1977) 717 – 723.
- 31 M. H. Wahdan, C. Sérié, Y. Cerisier, S. Sallam et al.: “A controlled field trial of live Salmonella typhi Ty 21 a oral vaccine against typhoid; three year results,” J. Infect. Dis. 145 (1982) 292 – 295.
- 32 World Health Organization Committee on Biological Standardization: Requirement for typhoid vaccine (live-attenuated, Ty21 a, oral). World Health Organization Technical Report, series 700; Geneva, Switzerland: 34th report, 1984, pp. 48 – 68.
- 33
R. Germanier in
R. Germanier (ed.):
Typhoid fever,
Bacterial Vaccines,
Academic Press, Orlando,
FL
1984,
pp. 137 – 165.
10.1016/B978-0-12-280880-7.50010-9 Google Scholar
- 34
M. M. Levine,
C. Ferreccio,
R. E. Black,
R. Germanier,
Chilean Typhoid Committee:
“Large-scale field trial of Ty21 a live oral typhoid vaccine in enteric-coated capsule formulation,”
Lancet
ii
(1987)
1049 – 1052.
10.1016/S0140-6736(87)90480-6 Google Scholar
- 35 M. M. Levine, D. Herrington, J. R. Murphy, J. G. Morris et al.: Safety, infectivity, immunogenicity, and in vivo stability of two auxotrophic mutant strains of Samonella typhi, 541 Ty and 543 Ty, as live oral vaccine in humans, J. Clin. Invest. 79 (1987) 888 – 902.
- 36 I. L. Acharya, C. V. Lowe, R. Thapa, V. L. Gurubacharya et al.: “Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi,” N. Engl. J. Med. 317 (1987) 1101 –1104.
- 37 R. Austrian: “Of gold and pneumococci; a history of pneumococcal vaccines in South Africa,” Trans. Am. Clin. Climatol. Assoc. 89 (1977) 141 – 161.
- 38 C. M. MacLeod, M. R. Krauss: “Stepwise intratype transformation of pneumococcus from R to S by way of a variant intermediate in capsular polysaccharide production,” J. Exp. Med. 86 (1947) 439 – 453.
- 39 J. B. Robbins, R. Austrian, C.-J. Lee, S. C. Rastogi et al.: “Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types,” J. Infect. Dis. 148 (1983) 1136 – 1159.
- 40 Health and Public Policy Committee, American College of Physicians: “Pneumococcal vaccine,” Ann. Intern. Med. 104 (1986) 118 – 120.
- 41 P. Smit, D. Oberholzer, S. Hayden-Smith, H. J. Koornhof et al.: “Protective efficacy of pneumonococcal polysaccharide vaccines,” JAMA J. Am. Med. Assoc. 238 (1977) 2613 – 2616.
- 42 G. Bolan, C. V. Broome, R. R. Facklam, B. D. Plikaytis et al.: “Pneumococcal vaccine efficacy in selected populations in the United States,” Ann. Intern. Med. 104 (1986) 1 – 6.
- 43 M. S. Simberkoff, A. P. Cross, M. Al-Ibrahim, A. L. Baltch et al.: “Efficacy of pneumococcal vaccine in high-risk patients,” N. Engl. J. Med. 315 (1986) 1318 – 1327.
- 44 J. A. Leech, A. Gervais, F. L. Ruben: “Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease,” Can. Med. Assoc. J. 136 (1987) 361 – 365.
- 45 C. Chu, R. Schneerson, J. B. Robbins, S. C. Rastogi: “Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6 A polysaccharide-protein conjugates,” Infect. Immun. 40 (1983) 245 – 256.
- 46 R. Schneerson, J. R. Robbins, C. Chu, A. Sutton et al.: “Serum antibody response of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6 A capsular polysaccharide-protein conjugates,” Infect. Immun. 45 (1984) 582 – 591.
- 47 R. Schneerson, J. B. Robbins, J. C. Parke, Jr., C. Bell et al.: “Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6 A capsular polysaccharide-tetanus toxoid conjugates,” Infect. Immun. 52 (1986) 519 – 528.
- 48 A. D. O'Brien, M. R. Thompson, P. Gemski, B. P. Doctor et al.: “Biological properties of Shigella flexneri 2 A toxin and its serological relationship to Shigella dysenteriae 1 toxin,” Infect. Immun. 15 (1977) 796 – 798.
- 49 A. R. Higgins, T. M. Floyd, M. A. Kader: “Studies in shigellosis. III. A controlled evaluation of a monovalent Shigella vaccine in a highly endemic environment,” Am. J. Trop. Med. Hyg. 4 (1955) 281 – 288.
- 50 D. M. Mel, E. J. Gangarosa, M. L. Radovanović, B. L. Arsić et al.: “Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains,” Bull. W.H.O. 45 (1971) 457 – 464.
- 51 M. M. Levine, P. A. Rice, E. J. Gangarosa, G. K. Morris et al.: “An outbreak of Sonnei shigellosis in a population receiving oral attenuated shigella vaccines,” Am. J. Epidemiol. 99 (1973) 30 – 36.
- 52
S. B. Formal,
M. M. Levine in
R. Germanier (ed.):
Shigellosis,
Bacterial Vaccines,
Academic Press,
Orlando, FL
1984,
pp. 167 – 186.
10.1016/B978-0-12-280880-7.50011-0 Google Scholar
- 53 S. B. Formal, L. S. Baron, D. J. Kopecko, O. Washington et al.: “Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei Form I antigen genes into the gal ε Salmonella typhi Ty 21 a typhoid vaccine strain,” Infect. Immun. 34 (1981) 746 – 750.
- 54 R. E. Black, M. M. Levine, M. L. Clements, G. Losonsky et al.: “Prevention of shigellosis by a Salmonella typhi – Shigella sonnei bivalent vaccine,” J. Infect. Dis. 155 (1987) 1260 – 1265.
- 55 L. S. Baron, D. J. Kopecko, S. B. Formal, R. Seid et al.: “Introduction of Shigella flexneri 2 a type and group antigen genes into oral typhoid vaccine strain Salmonella typhi Ty 21 a,” Infect. Immun. 55 (1987) 2797 – 2801.
- 56 S. Sturm, K. Timmis: “Cloning of the rfb gene region of Shigella dysenteriae 1 and construction of an rfb-rfp gene cassette for the development of lipopolysaccharide-based live anti-dysentery vaccines,” Microb. Pathog. 1 (1986) 289 – 297.
- 57 R. A. Finkelstein: “Immunology of cholera,” Immunol. 69 (1975) 137 – 195.
- 58 R. A. Finkelstein: “Cholera,” CRC Crit. Rev. Microbiol. 2 (1973) 553 – 623.
- 59 R. A. Cash, S. I. Music, J. P. Libonati, J. P. Craig et al.: “Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine,” J. Infect. Dis. 130 (1974) 325 – 333.
- 60 R. A. Cash, S. I. Music, J. P. Libonati, A. R. Schwartz et al.: “Live oral cholera vaccine; evaluation of the clinical effectiveness of two strains in humans,” Infect. Immun. 10 (1974) 762 – 764.
- 61 W. E. Woodward, R. H. Gilman, R. B. Hornick, J. P. Libonati et al.: “Efficacy of a live oral cholera vaccine in human volunteers,” Dev. Biol. Stand. 33 (1976) 108 – 112.
- 62 M. M. Levine, R. E. Black, M. L. Clements, C. Lanata et al.: “Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine, Infect. Immun. 43 (1984) 515 – 522.
- 63
J. B. Kaper,
M. M. Levine:
“Cloned cholera enterotoxin genes in study and prevention of cholera,”
Lancet
ii
(1981)
1162 – 1163.
10.1016/S0140-6736(81)90605-X Google Scholar
- 64 J. J. Mekalanos, D. J. Suartz, G. D. N. Pearson, N. Harford et al.: Cholera toxin genes: nucleotide sequence, deletion analysis, and vaccine development, Nature (London) 306 (1983) 551 – 557.
- 65 A. D. O'Brien, M. E. Chen, R. K. Holmes et al.: Environmental and human isolates of Vibrio cholerae and Vibrio parahaemolyticus produce a Shigella dysenteriae 1 (Shiga)-like cytotoxin,” Lancet i (1984) 77 – 78.
- 66
J. D. Clements,
J. R. Harris,
M. R. Khan,
B. A. Kay
et al.:
“Field trial of oral cholera vaccine in Bangladesh,”
Lancet
ii
(1986)
124 – 127.
10.1016/S0140-6736(86)91944-6 Google Scholar
- 67 J. E. McGowan, M. W. Barnes, M. Finland: “Bacteremia at Boston City Hospital; occurrence and mortality during 12 selected years (1935 – 1972), with special reference to hospital-acquired cases,” J. Infect. Dis. 132 (1975) 316 – 335.
- 68 C. S. Bryan, K. L. Reynolds, E. R. Brenner: “Analysis of 1186 episodes of gram-negative bacteremia in non-university hospitals; the effects of antimicrobial therapy,” Rev. Infect. Dis. 5 (1983) 629 – 638.
- 69 R. W. Haley: Preliminary cost-benefit analysis of hospital infection control programs (The SENIC Project), Proc. Internat. Workshop, Baiersbromm, Germany (1977) pp. 93 – 95.
- 70 S. J. Cryz, Jr. “Prospects for the prevention and control of gram-negative nosocomial infections,” Vaccine 5 (1987) 261 – 265.
- 71 W. R. Jarvis, J. W. White, V. P. Munn, J. L. Mosser et al.: “Nosocomial infection surveillance,” 1983. Centers for Disease Control Surveillance Summaries 33, no. 299, pp. 955 – 2155 (1985).
- 72 M. S. Pollack, L. S. Young: “Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man,” J. Clin. Invest. 63 (1979) 276 – 286.
- 73
S. J. Cryz, Jr., in
R. Germanier (ed.):
Pseudomonas aeruginosa infections,
Bacterial Vaccines,
Academic Press,
Orlando, FL
1984,
pp. 317 – 351.
10.1016/B978-0-12-280880-7.50016-X Google Scholar
- 74 G. B. Pier, S. E. Bennett: “Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide,” J. Clin. Invest. 77 (1986) 491 – 495.
- 75 S. J. Cryz, Jr., E. Fürer, A. S. Cross, A. Wegmann et al.: “Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine in humans,” J. Clin. Invest. 80 (1987) 51 – 56.
- 76 S. J. Cryz, Jr., A. S. Cross, E. Fürer, N. Chariatte, et al.: “Activity of intravenous immune globulin against Klebsiella,” J. Lab. Clin. Med. 108 (1986) 182 – 189.
- 77 W. D. Welch, W. J. Martin, P. Stevens, L. S. Young: “Relative opsonic and protective activities of antibodies against Kl, O and lipid A antigens of Escherichia coli,” Scand. J. Infect. Dis. 11 (1979) 291 – 298.
- 78 B. Kaijser, S. Ahlstedt: “Protective capacity of antibodies to Escherichia coli O and K antigens,” Infect. Immun. 17 (1977) 286 – 289.
- 79 A. S. Cross, P. Gemski, J. C. Sadoff, F. Ørskov et al.: “The importance of the Kl capsule in invasive infections caused by Escherichia coli,” J. Infect. Dis. 149 (1984) 184 – 193.
- 80 M. Granström, I. Julander, R. Möllby: “Serological diagnosis of deep Staphylococcus aureus infections by enzyme-linked immunosorbent assay (ELISA) for staphylococcal hemolysin and teichoic acid,” Scand. J. Infect. Dis. Suppl. 41 (1983) 132 – 139.
- 81 W. W. Karakawa, J. M. Fournier, W. F. Vann, R. Arbeit et al.: “Method for the serological typing of the capsular polysaccharides of Staphylococcus aureus,” J. Clin. Microbiol. 22 (1985) 445 – 447.
- 82 H. K. Hochkeppel, D. G. Braun, W. Visher, A. Imm et al.: “Serotyping and electron microscopy studies of Staphylococcus aureus clinical isolates with monoclonal antibodies to capsular polysaccharide types 5 and 8,” J. Clin. Microbiol. 25 (1987) 526 – 530.
- 83 R. D. Arbeit, J. M. Nelles: “Capsular polysaccharide antigenemia in rats with experimental endocarditis due to Staphylococcus aureus,” J. Infect. Dis. 155 (1987) 242 – 246.
- 84 L. M. Mutharia, G. Crockford, W. C. Bogard, Jr., R. E. W. Hancock: “Monoclonal antibodies specific for Escherichia coli J 5 lipolysaccharide: cross-reaction with other gram-negative bacterial species,” Infect. Immun. 45 (1984) 631 – 636.
- 85 E. J. Ziegler, J. A. McCutchan, H. Douglas, A. I. Braude: “Treatment of E. coli and Klebsiella bacteremia in agranulocytopenic animals with antiserum to a UDP-GAL epimerase-deficient mutant,” J. Immunol. 111 (1973) 433 – 438.
- 86 E. J. Ziegler, J. A. McCutchan, J. Fierer, M. P. Glauser et al.: “Treatment of gramnegative bacteremia and shock with human antiserum to a mutant of Escherichia coli,” N. Engl. J. Med. 307 (1982) 1225 – 1230.
- 87 J. D. Baumgartner, M. P. Glauser, J. A. McCutchan, E. J. Ziegler et al.: “Prevention of gramnegative shock and death in surgical patients by antibody to endotoxin core glycolipid,” Lancet ii (1985) 59 – 63.
- 88 J. D. Band, M. E. Chamberland, T. Platt, R. E. Weaver et al.: “Trends in meningococcal disease in the United States, 1975 – 1980,” J. Infect. Dis. 148 (1983) 754 – 758.
- 89
E. C. Gotschlich in
R. Germanier (ed.):
Meningococcal meningitis,
Bacterial Vaccines,
Academic Press,
Orlando, FL
1984,
pp. 237 – 255.
10.1016/B978-0-12-280880-7.50013-4 Google Scholar
- 90 L. Lapeyssonnie: “La meningite cerebro-spinale en Afrique,” Bull. W.H.O. 28 (1963) 1 – 114.
- 91 E. C. Gotschlich, I. Goldschneider, M. S. Artenstein: “Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers; J. Exp. Med. 129 (1969) 1367 – 1384.
- 92 M. S. Artenstein, R. Gold, J. G. Zimmerly, F. A. Wyle et al.: “Prevention of meningococcal disease by group C polysaccharide vaccine,” N. Engl. J. Med. 282 (1970) 417 – 420.
- 93 P. H. Mäkelä et al.: “Effect of group-A meningococcal vaccine in army recruits in Finland,” Lancet ii (1975) 883 – 886.
- 94 M. H. Wahdan, S. A. Sallam, M. N. Hassan, A. A. Gawad et al.: “A second controlled field trial of a serogroup A meningococcal vaccine in Alexandria,” Bull. W.H.O. 55 (1977) 645 – 651.
- 95 H. Peltola, P. H. Mäkelä, H. M. Käyhty, H. Jousimies et al.: “Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age,” N. Engl. J. Med. 297 (1977) 686 – 691.
- 96 H. J. Jennings, C. Lugowski: “Immunochemistry of groups A, B and C meningococcal polysaccharide-tetanus toxoid conjugates,” J. Immunol. 127 (1981) 1011 – 1018.
- 97 C. E. Frasch: “Prospects for the prevention of meningococcal disease: special reference to group B,” Vaccine 5 (1987) 3 – 4.
- 98 W. D. Zollinger, R. E. Mandrell, J. M. Griffis in J. B. Robbins, J. C. Hill, J. C. Sadoff (eds.): Enhancement of immunological activity by monovalent complexing of meningococcal group B polysaccharide and outer membrane protein, Seminars in Infectious Disease, vol. 4, Thieme-Stratton, New York 1982, pp. 254 – 262.
- 99 C. E. Frasch, G. Coetzee, D. M. Zahradrik, L. Y. Wang in G. K. Schoolnik (ed.): New developments in meningococcal vaccines, Pathogenic Neisseria, American Society for Microbiology, Washington, D.C. 1985, pp. 633 – 640.
- 100
F. M. Collins in
R. Germanier (ed.):
Tuberculosis,
Bacterial Vaccines,
Academic Press,
Orlando, FL
1984,
pp. 373 – 418.
10.1016/B978-0-12-280880-7.50018-3 Google Scholar
- 101 R. G. Ferguson, A. B. Simes: “BCG vaccination of Indian infants in Saskatchewan,” Tubercle 30 (1949) 5 – 11.
- 102 S. V. Boyden: “The effect of previous injections of tuberculoprotein on the development of tuberculin sensitivity following B.C.G. vaccination in guinea pigs,” Br. J. Exp. Pathol. 38 (1957) 611 – 617.
- 103 A. Lotte, O. Wasz-Höckert, F. Lert, N. Dumitrescu et al.: “Balance of risks and balance of cost regarding tuberculosis and antituberculosis vaccination,” Dev. Biol. Stand. 43 (1979) 111 – 119.
- 104 R. Torriani, A. Zimmermann, A. Morell: “Die BCG-Sepsis als letale Komplikation der BCG-Impfung,” Schweiz. Med. Wochenschr. 109 (1979) 708 –713.
- 105 W. Hennessen, H. Freudenstein, H. Engelhardt: “Observations on a BCG vaccine causing adverse reactions in newborns,” J. Biol. Stand. 5 (1977) 139 – 146.
- 106
D. B. Travers:
“BCG vaccination,”
Lancet
i
(1981)
1001 – 1002.
10.1016/S0140-6736(81)91767-0 Google Scholar
- 107 M. C. Lu, M. H. Lien, R. E. Becker, H. C. Heine et al.: “Genes for immunodominant protein antigens are highly homologous in Mycobacterium tuberculosis, Mycobacterium africanum, and the vaccine strain Mycobacterium bovis BCG,” Infect. Immun. 55 (1987) 2378 – 2382.
- 108 B. Moss, C. Flexner: “Vaccinia virus expression vectors,” Ann. Rev. Immunol. 5 (1987) 305 – 324.
- 109 H. Leffler, C. Svanborg-Eden: “Glycolipid receptors for uropathogenic E. coli attaching to human urinary tract epithelial cells and agglutinating human erythrocytes,” FEMS Microbiol. Lett. 8 (1980) 127 – 134.
- 110 K. Rauss, I. Kétyi, E. Matusovits, L. Szendrei et al.: “Specific oral prevention of infantile enteritis. III. Experiments with corpuscular vaccine,” Acta. Microbiol. Acad. Sci. Hung. 19 (1972) 19 – 28.
- 111 E. Fürer et al.: “Protection against colibacillosis in neonatal piglets by immunization of dams with procholeragenoid,” Infect. Immun. 35 (1982) 887 – 894.
- 112 L. Doberescu, C. Huygelen: “Protection of piglets against neonatal E. coli enteritis by immunization of the sow with a vaccine containing heat-labile enterotoxin (LT), Zentralbl. Veterinärmed. Reihe A 23 (1976) 79 – 88.
- 113 R. L. Morgan, R. E. Isaacson, H. W. Micon, C. C. Brinton et al.: “Immunization of suckling pigs against enterotoxigenic Escherichia coli-induced diarrheal disease by vaccinating dams with purified 987 or K 99 pili; protection correlates with pilus homology of vaccine and challenge,” Infect. Immun. 22 (1978) 771 – 777.
- 114 M. M. Levine, R. E. Black, C. C. Brinton, Jr., M. L. Clements et al.: “Reactogenicity, immunogenicity and efficacy studies of Escherichia coli type 1 somatic pili parenteral vaccine in man, Scand. J. Infect. Dis. Suppl. 33 (1982) 83 – 95.
- 115 D. G. Evans, D. J. Evans, Jr., A. R. Opekun, D. Y. Graham in A. Tagliabue, R. Rappuoli, S. E. Piazzi (eds.): Oral whole cell vaccine protective against enterotoxigenic Escherichia coli diarrhea, Bacterial Vaccines and Local Immunity, Edita Da Sclavo Sp.A., Siena, Italy 1986, pp. 155 – 156.
- 116 M. M. Levine in R. Germanier (ed.): Escherichia coli infections,” Bacterial Vaccines, Academic Press, Orlando, FL 1984 pp. 187 – 235.
- 117 F. A. Klipstein, R. F. Engert, R. A. Houghton: “Protection in rabbits immunized with a vaccine of Escherichia coli heat-stable toxin cross-linked to the heat-labile toxin B subunit,” Infect. Immun. 40 (1983) 888 – 893.
- 118 J. Holmgren: “Actions of cholera toxin and the prevention and treatment of cholera,” Nature (London) 292 (1981) 413 – 417.
- 119 R. A. Finkelstein, C. V. Sciortino, L. C. Rieke, M. F. Burks et al.: “Preparation of procholigenoids from Escherichia coli heat-labile enterotoxins,” Infect. Immun. 45 (1984) 518 – 521.
- 120 M. A. Schmidt, P. O'Hanley, G. K. Schoolinik in A. Tagliabue, R. Rappuoli, S. E. Piazzi (eds.): Synthetic peptides protect against infection in a model of experimental pyelonephritis in mice,” Bacterial Vaccines and Local Immunity, Edita Da Sclavo Sp.A., Siena, Italy 1986, pp. 389 – 398.
- 121 E. C. Gotschlich in R. Germanier (ed.): ‘'Gonorrhea,” Bacterial Vaccines, Academic Press, Orlando, FL 1984, pp. 353 – 371.
- 122 D. S. Kellogg, Jr., I. R. Cohen, L. C. Norins, A. L. Schroeter et al.: “Neisseria gonorrhoeae. II. Colonial variation and pathogenicity during 35 months in vitro,” J. Bacteriol. 96 (1968) 596 – 605.
- 123 J. Swanson, S. J. Kraus, E. C. Gotschlich: “Studies on gonococcus infection. I. Pili and zones of adhesion; their relation to gonococcal growth patterns,” J. Exp. Med. 134 (1971) 886 – 906.
- 124 L. Greenberg, B. B. Diena, F. A. Ashton, R. Wallace et al.: “Gonococcal vaccine studies in Inuvik,” Can. J. Public Health 65 (1974) 29 – 33.
- 125 E. C. Tramont, J. W. Boslego: “Pilus vaccines,” Vaccine 3 (1985) 3 – 10.
- 126 C. C. Brinton, S. W. Wood, A. Brown, A. M. Labik et al. in : J. B. Robbins, J. Hill, J. C. Sadoff (eds.): The development of a Neisseria pilus vaccine for gonorrhea and meningococcal meningitis, Seminars in Infectious Disease, vol. 4, Bacterial Vaccines, Thieme-Stratton, Inc., New York 1982, pp. 140 – 159.
- 127 G. K. Schoolinik, J. Y. Tai, E. C. Gotschlich: “A pilus peptide vaccine for prevention of gonorrhea,” Prog. Allergy 33 (1983) 314 – 331.
- 128 J. B. Rothbard, R. Fernandez, L. Wang, N. N. H. Teng et al.: Antibodies to peptides corresponding to conserved sequence of gonococcal pilins block bacterial adhesion, Proc. Nat. Acad. Sci. U.S.A (2) (1985) 915 – 919.
- 129 M. S. Blake in G. G. Jackson, H. Thomas (ed.): “Functions of the outer membrane proteins of Neisseria gonorrhoeae,” The Pathogenesis of Bacterial Infections, Springer-Verlag, Berlin 1985, pp. 51 – 66.
- 130 T. M. Buchanan, M. S. Siegel, K. C. S. Chen, W. A. Pearce in J. B. Robbins, J. Hill, J. C. Sadoff (ed.): Development of a vaccine to prevent gonorrhea, Seminars in Infectious Disease, vol. 4, Bacterial Vaccines, Thieme-Stratton, Inc., New York 1982, pp. 160 – 164.
- 131 J. B. Robbins, R. Schneerson, M. Pittman in R. Germanier (ed.): Haemophilus influenzae type b infections,” Bacterial Vaccines, Academic Press, Orlando, FL 1984, pp. 289 – 316.
- 132 A. Sutton, R. Schneerson, S. Kendall-Morris, J. B. Robbins: “Differential complement resistance mediates virulence of Haemophilus influenzae type b,” Infect. Immun. 35 (1982) 95 – 104.
- 133 H. Peltola, H. Käyhty, A. Sivonen, P. H. Mäkelä: “Haemophilus influenzae type b capsular polysaccharide vaccine in children; a double-blind field study of 100 000 vaccines 3 months to 5 years of age in Finland,” Pediatrics 60 (1977) 730 – 737.
- 134 E. A. Mortimer, “Efficacy of Haemophilus b Polysaccharide Vaccine: an Enigma,” J. Am. Med. Assoc. 260 (1988) 1454 – 1455.
- 135 H. Käyhty, J. Eskola, H. Peltola, M. G. Stout et al.: “Immunogenicity in infants of a vaccine composed of Haemophilus influenzae type b capsular polysaccharide mixed with DPT or conjugated to diphtheria toxoid,” J. Infect. Dis. 155 (1987) 100 – 106.
- 136 A. A. Lenoir, P. D. Granoff, D. M. Granoff: “Immunogenicity of Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in 2- to 6-month-old infants,” Pediatrics 80 (1987) 283 – 287.
- 137 J. Eskola, H. Peltola, A. K. Takala, H. Käyhty et al.: “Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy,” N. Engl. J. Med. 317 (1987) 717 –722.
- 138 C. D. Mitchell, H. H. Balfour, Jr. “Measles control: So near and yet so far,” Prog. Med. Virol. 31 (1985) 1 – 42.
- 139 L. E. Markowitz, R. H. Bernier: “Immunization of young infants with Edmonston-Zagreb measles vaccine,” Pediatr. Infect. Dis. J. 6 (1987) 809 – 812.
- 140 WHO Expert Committee on Biological Standardization: WHO Tech. Rep. Ser. 329 (1966) 52 – 73.
- 141 WHO Expert Committee on Biological Standardization: WHO Tech. Rep. Ser. 673 (1982) .
- 142 Centers for Disease Control: “Measles – United States, 1986,” Morb. Mort. Wkly. Rep. 36 (1987) 301 – 305.
- 143 K. J. Bart, W. A. Orenstein, A. R. Hinman: “The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles,” Dev. Biol. Stand. 65 (1986) 45 – 52.
- 144 E. Norrby, G. Enders-Ruckle, V. ter Meulen: “Differences in the appearance of antibodies to structural components of measles virus after immunization with inactivated and live virus,” J. Infect. Dis. 132 (1975) 262 – 269.
- 145 T. M. Varsanyi, B. Morein, A. Löve, E. Norrby: “Protection against lethal measles virus infection in mice by immune-stimulating complexes containing the hemagglutinin or fusion protein,” J. Virol. 61 (1987) 3896 – 3901.
- 146 M. R. Hilleman: “Mumps vaccination,” in: Modern Trends in Medical Virology, vol. 2, Butterworths, London (1970) pp. 241 – 261.
- 147 K. Penttinen, K. Cantell, P. Somer, A. Poikolainen: “Mumps vaccination in the Finnish defense forces,” Am. J. Epidemiol. 88 (1968) 234 – 244.
- 148 M. R. Hilleman, R. E. Weibel, E. B. Buynak, J. Stokes, Jr. et al.: “Live, attenuated mumps-virus vaccine; 4. Protective efficacy as measured in a field evaluation,” N. Engl. J. Med. 276 (1967) 252 – 258.
- 149 Centers for Disease Control: “Efficacy of mumps vaccine – Ohio,” Morb. Mort. Wkly. Rep. 32 (1983) 391–398.
- 150 F. E. Andre, J. Peetermans: “Effect of simultaneous administration of live measles vaccine on the “take rate” of live mumps vaccine,” Dev. Biol. Stand. 65 (1986) 101 – 107.
- 151 R. Glück, J. M. Hoskins, A. Wegmann, M. Just et al.: “Rubini, a new live attenuated mumps vaccine virus strain for human diploid cells,” Dev. Biol. Stand. 65 (1986) 29 – 35.
- 152 WHO Expert Committee on biological standardization: WHO Tech. Rep. Ser. 760 (1987) .
- 153 Recommendation of the Immunization Practices Advisory Committee (ACIP): “Mumps vaccine,” Morb. Mort. Wkly. Rep. 31 (1982) 617 – 625.
- 154 K. Penttinen, E.-P. Helle, E. Norrby: “Differences in antibody response induced by formaldehyde inactivated and live mumps vaccines,” Dev. Biol. Stand. 43 (1979) 265 – 268.
- 155 A. Löve, R. Rydbeck, G. Utter, C. örvell et al.: ‘'Monoclonal antibodies against fusion protein are protective in necrotizing mumps meningoencephalitis,” J. Virol. 58 (1986) 220 – 222.
- 156 F. T. Perkins: “Licensed vaccines,” Rev. Infect. Dis. 7 (1985) Suppl. 1, 73 – 76.
- 157
S. A. Plotkin,
F. Buser:
“History of RA 27/3 rubella vaccine,”
Rev. Infect. Dis.
7
(1985)
Suppl. 1,
77 – 78.
10.1093/clinids/7.Supplement_1.S77 Google Scholar
- 158 WHO Expert Committee on Biological Standardization: WHO Tech. Rep. Ser. 610 (1977) 54 – 84.
- 159 WHO Expert Committee on Biological Standardization: WHO Tech. Rep. Ser. 658 (1981) .
- 160
J. A. Dudgeon:
“Selective immunization; Protection of the individual,”
Rev. Infect. Dis.
7
(1985)
Suppl. 1,
185 – 190.
10.1093/clinids/7.Supplement_1.S185 Google Scholar
- 161 Recommendation of the Immunization Practices Advisory Committee (ACIP): “Rubella prevention,” Morb. Mort. Wkly. Rep. 33 (1984) 301 – 318.
- 162 B. Christenson, M. Böttiger, L. Heller: “Mass vaccination program aimed at eradicating measles, mumps, and rubella in Sweden; first experience,” Br. Med. J. 287 (1983) 389 – 391.
- 163 Centers for Disease Control: “Rubella vaccination during pregnancy – United States, 1971 – 1986,” Morb. Mort. Wkly. Rep. 36 (1987) 457 – 461.
- 164 Recommendation of the Immunization Practices Advisory Committee (ACIP): “New recommended schedule for active immunization of normal infants and children,” Morb. Mort. Wkly. Rep 35 (1986) 577 – 579.
- 165 A. Deforest, S. S. Long, H. W. Lischner, J. A. C. Girone et al.: “Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines,” Pediatrics 81 (1988) 237 – 246.
- 166 H. Peltola, O. P. Heinonen: “Frequency of true adverse reactions to measles-mumps-rubella vaccine,” Lancet i (1986) 939 – 942.
- 167 A. M. Arbeter, L. Baker, S. E. Starr, S. A. Plotkin: “The combination measles, mumps, rubella and varicella vaccine in healthy children,” Dev. Biol. Stand. 65 (1986) 89 – 93.
- 168
L. B. Schonberger,
J. Kaplan,
R. Kim-Farley,
M. Moore
et al.:
“Control of paralytic poliomyelitis in the United States,”
Rev. Infect. Dis.
6
(1984)
Suppl. 2,
424 – 426.
10.1093/clinids/6.Supplement_2.S424 Google Scholar
- 169 J. Salk: “Commentary: Poliomyelitis vaccination – choosing a wise policy,” Pediatr. Infect. Dis. J. 6 (1987) 889 – 893.
- 170 G. S. Wilson: The hazards of immunization, University of London, The Athlone Press 1967.
- 171 A. B. Sabin: “Oral poliovirus vaccine: History of its development and use and current challenge to eliminate poliomyelitis from the world,” J. Infect. Dis. 151 (1985) 420 – 436.
- 172 A. B. Sabin: “Commentary: Is there a need for a change in poliomyelitis immunization policy?” Pediatr. Infect. Dis. J. 6 (1987) 887 – 889.
- 173 M. Böttiger: “Experiences of vaccination with inactivated poliovirus vaccine in Sweden,” Dev. Biol. Stand. 47 (1981) 227 – 232.
- 174 K. Lapinleimu, M. Stenvik: “Experiences with polio vaccination and herd immunity in Finland,” Dev. Biol. Stand. 47 (1981) 241 – 246.
- 175 H. Bijkerk: “Poliomyelitis in the Netherlands,” Dev. Biol. Stand. 47 (1981) 233 – 240.
- 176 WHO Expert Committee on Biological Standardization: WHO Tech. Rep. Ser. 687 (1983) 107 – 174.
- 177 A. M. Mcbean, J. F. Modlin: “Rationale for the sequential use of inactivated poliovirus vaccine and live attenuated poliovirus vaccine for routine poliomyelitis immunization in the United States,” Pediatr. Infect. Dis. J. 6 (1987) 881 – 887.
- 178 K. Lapinleimu: “Sero-immune pattern of poliomyelitis type I and III in a population vaccinated with inactivated polio vaccine,” in: Proceedings of the 11th Symposium of the European Association Against Poliomyelitis and Allied Diseases, Rome 1966, Brussels; European Association Against Poliomyelitis, 1967, pp. 119 – 25.
- 179 A. L. van Wezel, G. van Steenis, Ch. A. Hannik, H. Cohen: “New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines,” Dev. Biol. Stand. 41 (1978) 159 – 168.
- 180
S. E. Robertson,
H. P. Traverso,
J. A. Drucker,
E. Z. Rovira
et al.:
“Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine,”
Lancet
i
(1988)
897 – 899.
10.1016/S0140-6736(88)91711-4 Google Scholar
- 181 B. J. Montagnon, B. Fanget, A. J. Nicolas: “The large-scale cultivation of vero cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine,” Dev. Biol. Stand. 47 (1981) 55 – 64.
- 182 WHO Expert Committee on Biological Standardization: WHO Tech. Rep. Ser. 745 (1987) .
- 183 Prevention of liver cancer: WHO Tech. Rep. Ser. 691 (1983) .
- 184 A. A. McLean: “Development of vaccines against Hepatitis A and Hepatitis B,” Rev. Infect. Dis. 8 (1986) 591 – 598.
- 185 W. Szmuness, C. E. Stevens, E. J. Harley, E. A. Zang et al.: “Hepatitis B vaccine; Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States,” N. Engl. J. Med. 303 (1980) 833 – 841.
- 186 WHO Expert Committee on Biological Standardization: WHO Tech. Rep. Ser. 725 (1985) 102 – 133.
- 187 Recommendation of the Immunization Practices Advisory Committee (ACIP): “Recommendations for protection against viral hepatitis,” Morb. Mort. Wkly. Rep. 34 (1985) 313 – 335.
- 188 Recommendation of the Immunization Practices Advisory Committee (ACIP): “Update on Hepatitis B prevention,” Morb. Mort. Wkly. Rep. 36 (1987) 353 – 366.
- 189 G. Eder, J. L. McDonel, F. Dorner: “Hepatitis B vaccine,” in: Progress in Liver Diseases, vol. 8, Grune and Stratton, New York 1986, pp. 367 – 394.
- 190 A. Zuckerman: “Tomorrow's hepatitis B vaccines,” Vaccine 5 (1987) 165 – 167.
- 191 D. N. Standring, W. J. Rutter: “The molecular analysis of hepatitis B virus,” in: Progress in Liver Diseases, vol. 8, Grune and Stratton, New York 1986, pp. 311 – 333.
- 192 WHO Expert Committee on Rabies: WHO Tech. Rep. Ser. 709 (1984) .
- 193 Centers for Disease Control: “Bat-rabies – Europe,” Morb. Mort. Wkly. Rep. 35 (1986) 430 – 432.
- 194 P. Sureau: “Rabies vaccine production in animal cell cultures,” Adv. Biochem. Eng. Biotechnol. 34 (1987) 111 – 128.
- 195 B. D. Perry: “Rabies,” Vet. Clin. North. Am. Small Anim. Pract. 17 (1987) 73 – 89.
- 196
H. Wilde,
P. Chomchey,
S. Prakongsri,
P. Punyaratabandhu:
“Safety of equine rabies immune globulin,”
Lancet
ii
(1987)
1275.
10.1016/S0140-6736(87)91885-X Google Scholar
- 197 Centers for Disease Control: “Human rabies despite treatment with rabies immune globulin and human diploid cell rabies vaccine – Thailand,” Morb. Mort. Wkly. Rep. 36 (1987) 759 – 765.
- 198 Centers for Disease Control: “Systemic allergic reactions following immunization with human diploid cell rabies vaccine,” Morb. Mort. Wkly. Rep. 33 (1984) 185 – 187.
- 199 M. C. Swanson, E. Rosanoff, M. Gurwith, M. Deitch et al.: “IgE and IgG antibodies to β-propiolactone and human serum albumin associated with urticarial reactions to rabies vaccine,” J. Infect. Dis. 155 (1987) 909 – 913.
- 200 M. Granström, M. Eriksson, G. Edevåg: “A sandwich ELISA for bovine serum in viral vaccines,” J. Biol. Stand. 15 (1987) 193 – 197.
- 201 B. Morein, K. Simons: “Subunit vaccines against enveloped viruses; virosomes, micelles and other protein complexes,” Vaccine 3 (1985) 83 – 93.
- 202 C. H. Stuart-Harris, G. C. Schild: Influenza, The Viruses and Disease, E. Arnoldt Ltd, London 1976.
- 203 P. F. Wright, D. T. Karzon: “Live Attenuated Influenza Vaccines,” Prog. Med. Virol. 34 (1987) 70 – 88.
- 204 WHO Expert Committee on Biological Standardization: WHO Techn. Rep. Ser. 638 (1979) .
- 205 Recommendations of the Immunization Practices Advisory Committee (ACIP): “Prevention and Control of Influenza,” Morb. Mort. Wkly. Rep. 36 (1987) 373 – 387.
- 206 P. A. Gross, A. L. Gould, A. E. Brown: “Effect of cancer chemotherapy on the immune response to influenza virus vaccine: Review of published studies,” Rev. Infect. Dis. 7 (1985) 613 – 618.
- 207 M. A. Strassburg, S. Greenland, F. J. Sorvillo, L. E. Lieb et al.: “Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports,” Vaccine 4 (1986) 38 – 44.
- 208 J. M. Ostrove, G. Inchauspe: “The biology of varicella-zoster virus” in: S. E. Straus “Varicella-zoster virus infections: biology, natural history, treatment, and prevention,” Ann. Intern. Med. 108 (1988) 221 –237.
- 209 M. Takahashi: “Clinical overview of varicella vaccine; Development and early studies,” Pediatrics 78 (1986) Suppl., 736 – 741.
- 210 R. E. Weibel, B. J. Neff, B. J. Kuter, H. A. Guess et al.: “Live attenuated varicella virus vaccine. Efficacy trial in healthy children,” N. Engl. J. Med. 310 (1984) 1409 – 1415.
- 211 A. A. Gershon, S. P. Steinberg, L. Gelb, and The National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group: “Live attenuated varicella vaccine use in immunocompromised children and adults,” Pediatrics 78 (1986) Suppl., 757 – 762.
- 212 Arthropod-borne and rodent-borne viral diseases: WHO Tech. Rep. Ser. 719 (1985).
- 213 Viral haemorrhagic fevers: WHO Tech. Rep. Ser. 721 (1985) .
- 214 K. C. Smithburn, C. Durieux, R. Koerber, H. A. Penna et al.: Yellow Fever Vaccination, World Health Organization, Geneva 1956.
- 215 J. C. Roche, A. Jouan, B. Brisou, R. Rodhain et al.: “Comparative clinical study of a new 17 D thermostable yellow fever vaccine,” Vaccine 4 (1986) Suppl., 163 – 165.
- 216 WHO Expert Committee on Biological Standardization: WHO Tech. Rep. Ser. 594 (1976) 23 – 49.
- 217 A. A. Smorodintsev, A. V. Dubov, V. I. Ilyenko, V. G. Platonov: “A new approach to development of live vaccine against tick-borne encephalitis,” J. Hyg. 67 (1969) 13 – 20.
- 218 C. Kuntz, F. X. Heinz, H. Hofmann: “Immunogenicity and reactogenicity of a highly purified vaccine against tick-borne encephalitis,” J. Med. Virol. 6 (1980) 103 – 109.
- 219 A. Oya in H. Fukumi (ed.): Japanese encephalitis vaccine, The vaccination. Theory and practice, International Medical Foundation of Japan (1975) pp. 69 – 82.
- 220 WHO Expert Committee on Biological Standardization: WHO Tech. Rep. Ser. 323 (1966) 56 – 71.
- 221 Recommendation of the Immunization Practices Advisory Committee (ACIP): Smallpox Vaccine Morb. Mort. Wkly. Rep. 34 (1985) 341 – 342.
- 222 R. Randall, L. N. Binn, V. R. Harrison: “Immunization against Rift Valley fever virus,” J. Immunol. 93 (1964) 293 – 299.
- 223 B. Niklasson: “Rift Valley fever virus vaccine trial; Study of side effects in humans,” Scand. J. Infect. Dis. 14 (1982) 105 – 109.
- 224 P. M. Kaye, Parasitol. Today 3 (1987) 293 – 299.
- 225 M. D. Rickard, M. J. Howell in E. E. R. Taylor, J. R. Baker (ed.): In Vitro Methods for Parasite Cultivation, Academic Press, London 1987, pp. 407 – 451.
- 226
G. Piekarski:
Medizinische Parasitologie,
Springer Verlag,
Berlin
1987.
10.1007/978-3-662-08635-3 Google Scholar
- 227 V. Houba in V. Houba (ed.): Immunological Investigation of Tropical Parasitic Diseases, Churchill Livingstone, Edinburgh 1980, pp. 130 – 147.
- 228 P. Hagan, P. J. Moore, A. B. Adjukiewicz, B. M. Greenwood et al.: Parasite Immunol. 7 (1985) 617 – 624.
- 229 A. E. Butterworth, M. Capron, J. S. Cordingley, P. R. Dalton, Trans. R. Soc. Trop. Med. Hyg. 79 (1985) 393 – 408.
- 230 G. Gazzinelli, J. R. Lambertucci, N. Katz, R. S. Rocha, J. Immunol. 135 (1985) 2121 – 2127.
- 231 C. W. Todd, R. W. Goodgame, D. Colley, J. Immunol. 122 (1979) 1440 – 1446.
- 232 R. F. Sturrock, R. Kimani, B. I. Cottrell, A. E. Butterworth, Trans. R. Soc. Trop. Med. Hyg. 77 (1983) 363 – 371.
- 233 A. E. Butterworth, R. F. Sturrock, V. Houba, A. A. F. Mahmoud, Nature (London) 256 (1975) 727 – 729.
- 234 A. E. Butterworth, Adv. Parasitol. 23 (1984) 143 – 235.
- 235 S. R. Smithers, R. J. Terry, Adv. Parasitol. 14 (1976) 399 – 422.
- 236 A. Capron, Fortschr. Zool. 27 (1982) 259 – 264.
- 237 A. E. Butterworth, P. Hagan, Parasit. Today 3 (1987) 11 – 16.
- 238 A. J. G. Simson, D. Cioli, Parasit. Today 3 (1987) 26 – 28.
- 239 C. Dissous, I. M. Crzych, A. Capron, J. Immunol. 129 (1982) 2232 – 2234.
- 240 Q. D. Bickle, B. I. Andrews, M. G. Taylor, Parasit Immunol. 8 (1986) 95 – 107.
- 241 C. Kelly, A. I. G. Simpson, E. Fox, S. M. Phillips et al.: Parasit Immunol. 8 (1986) 193 – 198.
- 242 J. M. Balloul, P. Sondermeyer, D. Dreyer, M. Capron, Nature (London) 326 (1987) 149 – 153.
- 243 D. Wakelin: Immunity to Parasites, Edward Arnold Ltd., London 1984.
- 244 S. Friedmann, Gen Eng. News (1985) 24 – 25.
- 245 V. K. Vinayak, N. K. Gupta, A. K. Chopra, G. L. Sharma et al., Parasitology 82 (1981) 375 – 382.
- 246 P. Ambroise-Thomas in V. Houba (ed.): Immunological Investigation of Tropical Parasitic Diseases, Churchill Livingstone, Edinburgh 1980, pp. 84 – 103.
- 247 B. M. Ogilvie, M. J. Worms in S. Cohen, E. H. Sadun (eds.): Immunology of Parasitic Infections, Blackwell Scientific Publ., Oxford 1976, 397 – 402.
- 248 M. M. Wong, H. I. Fredericks, C. P. Ramachandran, Bull. W.H.O. 40 (1969) 493 – 501.
- 249 C. P. Ramachandran, Southeast Asian J. Trop. Med. Public Health 1 (1970) 78 – 92.
- 250 A. Haque, A. Capron in T. W. Pearson (ed.): Parasite Antigens, Marcel Dekker Inc., New York 1986, pp. 317 – 402.
- 251 R. M. Maizels, F. Partono, Sri Oemijati, D. A. Denham et al., Parasitology 87 (1983) 249 – 263.
- 252 M. D. Rickard in C. Arme, P. W. Pappas (eds.): Biology of the Eucestoda, Academic Press, London 1983, pp. 539 – 579.
- 253 M. D. Rickard, F. F. Williams, Adv. Parasitol. 21 (1982) 229 – 296.
- 254 R. P. Herd, R. I. Chappel, D. Biddell, Int. J. Parasitol. 5 (1975) 395 – 399.
- 255 D. J. Jenkins, M. D. Rickard, Aust. Vet. J. 63 (1986) 40 – 42.
- 256 R. S. Nussenzweig, J. Vanderberg, H. Most, C. Orton, Nature (London) 216 (1967) 160 – 162.
- 257 W. A. Siddiqui, Science 197 (1977) 388 – 389.
- 258 G. H. Mitchell, W. H. G. Richards, G. A. Butcher, S. Cohen, Lancet (i) (1977) 1335 – 1358.
- 259 W. Trager, J. B. Jensen, Science 193 (1976) 673 – 675.
- 260 D. Mazier, R. L. Beaudoin, S. Mellouk, P. Druilhe et al., Science 227 (1985) 440 – 442.
- 261 C. Guerin-Marchand, P. Druilhe, B. Galey, A. Londono et al., Nature (London) 329 (1987) 164 – 167.
- 262 A. H. Cochrane in J. P. Kreier (ed.): Malaria, Immunology and Immunization vol. 3, Chap. 4, Academic-Press, New-York, 1980.
- 263 D. F. Clyde, Am. J. Trop. Med. Hyg. 24 (1975) 397 – 401.
- 264 E. H Nardin, R. S. Nussenzweig, I. A. McGregor, J. H. Bryan, Science 206 (1979) 597 – 599.
- 265 G. Del Giudice, H. D. Engers, C. Tougne, S. S. Biro et al., Am. J. Trop. Med. Hyg. 36 (1987) 203 – 212.
- 266 D. H. Chen, R. E. Tigelaar, F. I. Weinbaum, J. Immunol. 118 (1977) 1322 – 1327.
- 267 A. Ferreira, L. Schofield, V. Enea, H. Schellekins et al., Science 232 (1986) 881 – 884.
- 268 P. Potocnjak, N. Yoshida, R. S. Nussenzweig, V. Nussenzweig, J. Exp. Med. 151 (1980) 1504 – 1513.
- 269 D. Mazier, S. Mellouk, R. L. Beaudoin, B. Texier et al., Science 231 (1986) 156 – 159.
- 270 J. B. Dame, J. L. Williams, T. F. McCutchan, J. L. Weber et al., Science 225 (1984) 593 – 599.
- 271 V. Enea, J. Ellis, F. Zavala, D. E. Arnot et al., Science 225 (1984) 628 – 630.
- 272 D. J. Kemp, R. L. Coppel, R. F. Anders, Ann. Rev. Microbiol. 41 (1987) 181 – 208.
- 273 V. F. De la Cruz, A. A. Lal, T. F. McCutchan, J. Biol. Chem. 262 (1987) 11935 – 11941.
- 274 M. J. Lockyer, R. T. Schwarz, Mol. Biochem. Parasitol. 22 (1987) 101 – 107.
- 275 G. Del Giudice, A. S. Verdini, M. Pinori, J. P. Verhave et al., J. Clin. Microbiol. 25 (1987) 91 – 96.
- 276 S. L. Hoffman, R. Wistar, Jr., W. R. Ballou, M. R. Hollingdale et al., New-Engl. J. Med. 315 (1986) 601 – 603.
- 277 D. A. Herrington, D. F. Clyde, G. Losonsky, M. Cortesia et al., Nature (London) 328 (1987) 257 – 259.
- 278
W. R. Ballou,
S. L. Hoffman,
J. A. Sherwood,
M. R. Hollingdale
et al.,
Lancet
I
(1987)
1277 – 1279.
10.1016/S0140-6736(87)90540-X Google Scholar
- 279 G. Del Giudice, J. A. Cooper, J. Merino, A. S. Verdini et al., J. Immunol. 137 (1986) 2952 – 2955.
- 280 M. F. Good, J. A. Berzofsky, W. L. Maloy, Y. Hayashi et al., J. Exp. Med. 164 (1986) 655 –660.
- 281 A. R. Togna, G. Del Giudice, A. S. Verdini, F. Bonetti et al., J. Immunol. 137 (1986) 2956 – 2960.
- 282 M. F. Good, D. Pombo, I. A. Quakyi, E. M. Riley et al., Proc. Natl. Acad. Sci. USA 85 (1988) 1199 – 1203.
- 283 L. H. Miller, S. J. Mason, D. F. Clyde, M. H. McGinis, New-Eng. J. Med. 295 (1976) 302 – 304.
- 284 M. J. Miller, Trans. Roy. Soc. Trop. Med. Hyg. 52 (1958) 152 – 158.
- 285 S. Cohen, I. A. McGregor, S. C. Carrington, Nature (London) 192 (1961) 733 – 735.
- 286 A. Celada, A. Cruchau, L. H. Perrin, Clin. Exp. Immunol. 47 (1982) 635 – 641.
- 287 P. H. David, Proc. Natl. Acad. Sci. USA 80 (1983) 5075 – 5081.
- 288 L. H. Miller, R. J. Howard, R. Carter, M. F. Good et al., Science 234 (1986) 1349 – 1356.
- 289 L. H. Perrin, E. Ramirez, L. Er-Hsiang, P.-H. Lambert; Clin. Exp. Immunol. 41 (1980) 91 – 106.
- 290 A. A. Holder, R. R. Freeman, J. Exp. Med. 156 (1982) 1528 – 1538.
- 291 J. S. McBride, D. Walliker, G. Morgan, Science 217 (1982) 254 – 256.
- 292 A. A. Holder, M. J. Lockyer, K. G. Odink, J. S. Sandhu et al., Nature (London) 317 (1985) 270 – 273.
- 293 K. G. Oding, M. J. Lockyer, S. C. Nicholls, Y. Hillman et al., FEBS Lett. 173 (1984) 108 – 112.
- 294 M. Mackay, M. Goman, N. Bone, J. E. Hyde et al., EMBO J. 4 (1985) 3823 – 3829.
- 295 L. H. Perrin, B. Merkli, M. Loche, C. Chizzolini et al., J. Exp. Med. 160 (1984) 441 – 447.
- 296 R. Hall, J. E. Hyde, M. Goman, D. L. Simmons et al., Nature (London) 311 (1984) 379 – 382.
- 297 W. A. Siddiqui, L. Q. Tam, K. J. Kramer, G. S. N Hui et al., Proc. Natl. Acad. Sci. USA 84 (1987) 3014 – 3018.
- 298 A. A. Holder, R. R. Freeman, Nature (London) 294 (1981) 361 – 363.
- 299 M. E. Patarroyo, P. Romero, M. L. Torres, P. Clavijo et al., Nature (London) 328 (1985) 629 – 631.
- 300 A. Cheung, J. Leban, A. R. Shaw, B. Merkli et al., Proc. Natl. Acad. Sci. USA 83 (1986) 8323 – 8332.
- 301 L. H. Perrin, R. Dayal, Immunol. Rev. 61 (1982) 245 – 268.
- 302 R. R. Freeman, A. J. Trejosiewicz, G. A. Cross, Nature (London) 284 (1980) 366 – 369.
- 303 L. H. Perrin, E. Ramirez, P.-H. Lambert, P. A. Miescher, Nature (London) 289 (1981) 301 – 303.
- 304 C. Braun-Breton, M. Jendoubi, E. Brunet, L. Perrin et al., Mol. Bioch. Parasitol. 20 (1986) 33 – 38.
- 305 C. Braun-Breton, T. L. Rosenberg, L. Pereira Da Silva, Nature (London) 332 (1988) 457 – 459.
- 306 U. Certa, P. Ghersa, H. Dobeli, H. Matile et al., Science 240 (1988) 1036 – 1038.
- 307 P. Dubois, J. P. Dedet, T. Fandeur, C. Roussilhon et al., Proc. Natl. Acad. Sci. USA 81 (1984) 229 – 335.
- 308 L. H. Perrin, B. Merkli, M. S. Gabra, J. Stocker et al., J. Clin. Invest. 75 (1985) 1718 – 1725.
- 309 J. F. Dubremetz, P. Delplace, B. Fortier, G. Tronchin et al., Mol. Biochem. Parasitol. 27 (1988) 135 – 142.
- 310 R. L. Coppel, J. G. Culvenor, A. E. Bianco, P. E. Crewther et al., Mol. Biochem. Parasitol. 25 (1987) 73 – 81.
- 311 H. Perlamnn, K. Berzins, M. Wahlgren, J. Carlsson et al., J. Exp. Med. 159 (1984) 1686 – 1693.
- 312 G. V. Brown, I. G. Culvenor, P. E. Crewther, A. E. Bianco et al., J. Exp. Med. 162 (1985) 774 – 779.
- 313 B. Wahlin, M. Wahlgren, H. Perlamnn, H. Berzins et al., Proc. Natl. Acad. Sci. USA 81 (1984) 7912 – 7916.
- 314 J. M. Favarolo, R. L. Coppel, L. M. Corcoran, S. J. Foote et al., Nucl. Acid. Res. 14 (1986) 8265 –8277.
- 315 W. E. Collins, R. F. Anders, M. Pappaioanou, G. H. Campbell et al., Nature (London) 323 (1986) 259 – 262.
- 316 S. A. Luse, L. H. Miller, Am. J. Trop. Med. Hyg. 20 (1971) 655 – 670.
- 317 T. Triglia, H. D. Stahl, P. E. Crewther, D. Scanlon et al., EMBO J. 6 (1987) 1413 – 1419.
- 318 M. Koenen, A. Scherf, O. Mercereau, G. Langsley et al., Nature (London) 311 (1984) 382 – 385.
- 319 I. J. Udeinya, L. H. Miller, I. A. McGregor, J. B. Jensen, Nature (London) 231 (1983) 429 – 431.
- 320 K. Marsh, R. J. Howard, Science 231 (1986) 150 – 153.
- 321 S. Pollack, J. Fleming, Brit. J. Haematol. 58 (1984) 289 – 294.
- 322 M. E. Perkins, J. Exp. Med. 160 (1984) 788 – 797.
- 323 D. Camus, T. J. Hadley, Science 230 (1985) 553 – 557.
- 324 P. Delplace, B. Fortier, G. Tronchin, J. F. Dubremetz et al., Mol. Biochem. Parasitol. 23 (1987) 193 – 202.
- 325 M. E. Patarroyo, R. Amador, P. Lavijo, A. Moreno et al., Nature (London) 332 (1988) 158 – 161.
- 326 R. W. Gwadz, Science 193 (1976) 1150 – 1153.
- 327 K. N. Mendis, G. A. T. Targett, Nature (London) 277 (1979) 289 – 391.
- 328 R. W. Gwadz, L. C. Koontz, Infect. Immun. 44 (1984) 137 – 145
- 329 N. Kumar, R. Carter, Mol. Biochem. Parasitol. 13 (1984) 333 – 341.
- 330 K. Mendis, P. Udayama, R. Carter, P. H. David, J. Cell Biochem. Suppl. 10 A (1986) 149 – 156.
- 331 A. N. Vermuelen, T. Ponnudurai, P. J. A. Beckers, J. P. Verhave et al., J. Exp. Med. 162 (1985) 1460 – 1476.
- 332 J. Rener, P. M. Graves, R. Carter, J. L. Williams et al., J. Exp. Med. 158 (1983) 976 – 980.
- 333 P. M. Graves, R. Carter, T. R. Burkot, J. Rener et al., Infect. Immun. 48 (1985) 611 – 619.
- 334 E. R. Stiehm, E. Ashida, K. S. Kim, D. J. Winston et al., Ann. Intern. Med. 107 (1987) 367 – 82.
- 335 E. R. Stiehm, Pediatrics 63 (1979) 301 – 19.
- 336 J. A. Finlayson, in C. S. F. Easmon, J. Jeljaszewics (eds.): Medical Microbiology, vol. 1, Academic Press, London 1982, pp. 129 – 82.
- 337 R. Heffron: Pneumonia, With Special Reference to Pneumococcus Lobar Pneumonia, The Commonwealth Fund, New York 1939.
- 338 R. H. Rousell, M. S. Collins, M. B. Dobkin, R. E. Louie et al., Am. J. Med. Suppl. 76 (1984) 40 – 5.
- 339 H. E. Alexander, Am. J. Dis. Child. 66 (1943) 172 – 87.
- 340 H. E. Alexander, Am. J. Dis. Child. 66 (1943) 160 – 71.
- 341 E. Merler, F. S. Rosen, N. Engl. J. Med. 275 (1966) 480 – 86;536 – 542.
- 342 C. A. Janeway, F. S. Rosen, N. Engl. J. med. 275 (1966) 826 – 31.
- 343 P. A. M. Gross, D. Gitlin, C. A. Janeway, N. Engl. J. Med. 260 (1959) 170 – 78.
- 344 J. Stokes, E. P. Maris, S. S. Gellis, J. Clin. Invest. 23 (1944) 531 – 40.
- 345 J. Stokes, J. R. Neefe, JAMA J. Am. Med. Assoc. 127 (1945) 531 – 40.
- 346 W. M. Hammon, L. L. Coriell, J. Stokes et al., JAMA J. Am. Med. Assoc. 150 (1950) 739 – 49;750 – 56.
- 347 C. A. Janeway, L. Apt, D. Gitlin, Trans. Assoc. Am. Physician 66 (1953) 200 – 202.
- 348 P. A. M. Gross, D. Gitlin, C. A. Janeway, N. Engl. J. Med. 260 (1959) 121 – 25.
- 349 R. G. Hamilton, Clin. Chem. (Winston Salem N.C.) 33 (1987) 1707 – 25.
- 350 G. R. Siber, P. H. Schur, A. C. Weitzman, G. Schiffman, N. Engl. J. Med. 303 (1980) 178 – 82.
- 351 C. M. Roifman, H. M. Lederman, S. Lavi, L. D. Stein et al., Am. J. Med. 79 (1985) 171 – 4.
- 352 S. Barandun, H. Isliker, Vox Sang. 51 (1986) 157 – 60.
- 353 A. Hassig, Vox Sang. 51 (1986) 10 – 17.
- 354 D. D. Schroeder, M. L. Dumas, Am. J. Med. Suppl. 76 (1984) 33 – 9.
- 355 C. A. Janeway, E. Merler, F. S. Rosen, S. Salmon et al., N. Engl. J. Med. 278 (1968) 919 – 23.
- 356 J. Passwell, F. S. Rosen, E. Merler in B. Alving, J. Finlayson (eds.): Immunoglobulins; characteristics and uses of intravenous preparations, U.S.Dept. H.H.S., Washington 1979, pp. 139 – 42.
- 357 H. D. Ochs, S. H. Fischer, R. J. Wedgwood, J. Clin. Immunol Suppl. 2 (1982) 22 S – 29 S.
- 358 C. Cunningham-Rundles, F. P. Siegal, E. M. Smithwick, A. Lion-Boule et al., Ann. Intern. Med. 101 (1984) 435 – 9.
- 359 M. S. Collins, J. H. Dorsey, J. Infect. Dis. 151 (1985) 1171 – 3.
- 360 J. R. Schreiber, V. A. Barrus, G. R. Siber, Infect. Immun. 47 (1985) 142 – 48.
- 361 H. D. Ochs et al., Lancet 2 (1980) 1158 – 9.
- 362 Medical Letter 24 (1982) 81 – 82.
- 363 R. H. Johnson, R. J. Ellis, Ann. Intern. Med. 81 (1974) 61 – 67.
- 364 C. Cunningham-Rundles, L. A. Hanson, W. H. Hitzig, W. Knapp et al., Bull. W.H.O. 60 (1982) 43 – 47.
- 365 S. Krugman, N. Engl. J. Med. 269 (1963) 195 – 201.
- 366
E. B. Grosman,
S. G. Stewart,
J. Stokes,
JAMA J. Am. Med. Assoc.
129
(1945)
991 – 94.
10.1001/jama.1945.02860490003002 Google Scholar
- 367 Medical Research Council Workingparty, Lancet 1 (1969) 163 – 8.
- 368 C. L. S. Leen, P L. Yap, D. B. L. McClelland, Vox Sang. 51 (1986) 278 – 86.
- 369 Lancet 1 (1983) 105 – 6.
- 370 G. Chirico, G. Rondini, A. Plebani, A. Chiara et al., J. Pediatr. 110 (1987) 437 – 42.
- 371 J. Amer, E. Ott, F. A. Ibbott, D. O'Brien et al., Pediatrics 32 (1963) 4 – 9.
- 372 A. A. Hertler, S. C. Ross, J. Clin. Lab. Immunol. 21 (1986) 177 – 81.
- 373 S. Baron, E. V. Barnet, R. S. Goldsmith, S. Silbergeld et al., Am. J. Hyg. 79 (1964) 186 – 95.
- 374 N. A. Kefalides, J. A. Arana, A. Bazan, M. Bocanegra et al., N. Engl. J. Med. 267 (1962) 317 – 24.
- 375 H. H. Stone, C. D. Graber, J. D. Martin, L. Kolb, Surgery St. Louis 58 (1965) 810 – 14.
- 376 R. J. Jones, E. A. Roe, J. L. Gupta, Lancet 2 (1980) 1263 – 5.
- 377 R. L. Wasserman, Pediatric Infectious Diseases 5 (1986) 620 – 21.
- 378 J. A. Steen, Arch. Pediatr. 77 (1960) 291 – 4.
- 379 A. P. Schless, G. S. Harell, Amer. J. Med. 44 (1968) 325 – 329.
- 380 M. Santosham, R. Reid, D. M. Ambrusino, M. C. Wolff et al., Engl. J. Med. 317 (1987) 923 – 9.
- 381 S. M. Rosenthal, R. C. Millican, J. Rust, Proc. Soc. Exp. Biol. Med. 94 (1957) 214 – 217.
- 382 M. W. Fisher, Antibiot. Chemother. (Washington D.C.) 7 (1957) 315 – 21.
- 383 M. W. Fisher, M. C. Manning, Antibiot. Chemother. (Washington D.C.) 8 (1958) 29 – 31.
- 384 B. A. Waisbren, Antibiot. Chemother. (Washington D.C.) 7 (1957) 322 – 33.
- 385 B. A. Waisbren, D. Lepley, Arch. Intern. Med. 109 (1962) 712 – 6.
- 386 G. P. Bodey, B. A. Nies, N. R. Mohberg, E. J. Freireich, JAMA J. Am. Med. Assoc. 190 (1964) 1099 – 1102.
- 387 K. C. Finkel, J. C. Haworth, Pediatrics 25 (1960) 798 – 806.
- 388 D. R. Snydman, B. G. Werner, B. Heinzer-Lacey, V. P. Berardi et al., N. Engl. J. Med. 317 (1987) 1049 – 54.
- 389 R. M. Condie, R. J. O'Reilly, Am. J. Med. 76 (Suppl. 30 March 1984) 134 – 41.
- 390 A. Hagenbeek, H. G. J. Brummelhuis, A. Donkers, A. M. Dumas et al., J. Infect. Dis. 155 (1987) 897 – 902.
- 391 D. J. Winston, W. G. Ho, C.-H. Lin, M. D. Budinger et al., Am. J. Med. 76 (Suppl. 30 March 1984) 128 – 33.
- 392 R. A. Bowden, M. Sayers, N. Flournoy, B. Newton et al., N. Engl. J. Med. 314 (1986) 1006 – 1010.
- 393 E. C. Reed et al., J. Infect. Dis. 156 (1987) 641 –44.
- 394 K. Erlendsson, T. Swartz, J. M. Dwyer, N. Engl. J. Med. 312 (1985) 351 – 3.
- 395 P. J. Mease, H. D. Ochs, R. J. Wedgood, N. Engl. J. Med. 304 (1981) 1278 – 81.
- 396 J. M. Crennan, R. E. Van Scoy, C. H. McKenna, T. F. Smith, Am. J. Med. 81 (1986) 35 – 42.
- 397
K. S. Erlich,
J. Mills,
Rev. Infect. Dis.
8
(1986)
S 439 – 45.
10.1093/clinids/8.Supplement_4.S439 Google Scholar
- 398 D. Ambrosino, J. R. Schreiber, R. S. Daum, G. R. Siber, Infect. Immun. 39 (1983) 709 – 14.
- 399 T. E. Harper, R. D. Christensen, G. Rothstein, Pediatr. Res. 22 (1987) 455 – 60.
- 400 S. J. Cryz, A. S. Cross, E. Furer, N. Chariatte et al., J. Lab. Clin. Med. 108 (1986) 182 – 89.
- 401 I. A. Holder, J. G. Naglich, Am. J. Med. 76 (1984) 161 – 67.
- 402 J. E. Pennington, G. J. Small, J. Infect. Dis. 155 (1987) 973 – 78.
- 403 V. G. Hemming, W. T. London, G. W. Fischer, B. L. Curfman et al., J. Infect. Dis. 156 (1987) 655 – 658.
- 404 K. N. Haque, M. H. Zaidi, S. K. Haque, H. Bahakim et al., Pediatric Infectious Diseases 5 (1986) 622 – 25.
- 405 D. Sidiropoulos, U. Herrmann, A. Morell, G. von Muralt et al., J. Pediatr. St. Louis 109 (1986) 505 – 508.
- 406 W. G. Ho, D. J. Winston, K. Bartoni, R. E. Champlin et al., Abstr. 456, 1983 Interscience Confer. Infect. Dis. Chemother., Las Vegas, Nevada.
- 407 C. Bunch, H. Chapel, K. R. Rai, R. P. Gale, Blood 70 (1987) 224 a (Abstr); N. Engl. J. Med. 319 (1988) 902 – 907.
- 408 H. D. Ochs, Pediatr. Infect. Dis. 6 (1987) 509 – 11.
- 409 C. C. Wood, J. G. McNamara, D. F. Schwarz, W. W. Merrill et al., Pediatr. Infect. Dis. 6 (1987) 564 – 66.
- 410 B. A. Silverman, A. Rubinstein, Am. J. Med. 78 (1985) 728 – 36.
- 411
D. Sidiropoulos,
U. Boehme,
G. von Muralt,
A. Morell
et al.,
Pediatr. Infect. Dis.
5
(1986)
193 –94.
10.1097/00006454-198605010-00009 Google Scholar
- 412 S. Barandun, P. Imbach, A. Morrell, H. P. Wagner in U. E. Nydegger (ed.): Immunohemotherapy. A guide to immunoglobulin prophylaxis and therapy, Academic Press, New York 1981, pp. 275 – 82.
- 413 P. Imbach, H. P. Wagner, W. Berchtold, G. Gaedicke et al., Lancet 2 (1985) 464 – 68.
- 414 J. Fehr, V. Hoffmann, U. Kappeler, N. Engl. J. Med. 306 (1982) 1254 – 58.
- 415 S. Rosthoj, G. K. Steffensen, T. K. Guld, Acta Paediatr. Scand. 76 (1987) 631 – 5.
- 416 R. Bohm, C. Hofstaetter, R. C. Briel, Blut 48 (1984) 469 – 70.
- 417 F. E. Leickly, R. H. Buckley, Am. J. Med. 82 (1987) 159 – 62.
- 418 G. W. Richmond, I. Ray, A. Korenblitt, J. Pediatr. (St. Louis) 110 (1987) 917 – 9.
- 419 M. W. Hilgartner, J. Bussel, Am. J. Med. 83 (1987) 35 – 9.
- 420 T. Becker, S. Panzer, D. Maas, V. Kiefel et al., Br. J. Haematol. 61 (1985) 149 – 55.
- 421 F. Dammacco, G. Iodice, N. Campobasso, Br. J. Haematol. 62 (1986) 125 – 35.
- 422 A. C. Newland, J. G. Treleaven, R. M. Minchinton, A. H. Waters, Lancet 1 (1983) 84 – 7.
- 423 J. B. Bussel, R. P. Kimberly, R. D. Inman, I. Schulmann et al., Blood 62 (1983) 480 – 6.
- 424 J. R. Duran-Suarez, A. Martin, M. C. Botella, S. de la Torre et al., Haematologica 68 (1983) 564 – 6.
- 425 C. A. Schiffer et al., Blood 64 (1984) 937 – 40.
- 426 G. Chirico, M. Duse, A. G. Ugazio, G. Rondini, J. Pediatr. (St. Louis) 103 (1983) 654 – 5.
- 427 E. C. Besa, M. W. McNab, A. J. Solan, M. J. Lapes et al., Am. J. Hematol. 18 (1985) 373 – 9.
- 428 W. A. McGuire, H. H. Yang, E. Bruno, J. Brandt et al., N. Engl. J. Med. 317 (1987) 1004 – 8.
- 429 C. De la Camara, R. Arrieta, A. Gonzalez, E. Iglesias et al., N. Engl. J. Med. 318 (1988) 519 – 20.
- 430 I. M. Nilsson, E. Berntorp, O. Zettervall, N. Engl. J. Med. 318 (1988) 947 – 50.
- 431 J. W. Newburger, M. Takahashe, J. C. Burns, A. S. Beiser et al., N. Engl. J. Med. 315 (1986) 341 – 7.
- 432 M. Nagashima, M. Matsushima, H. Matsuoka, A. Ogawa et al., J. Pediatr. (St. Louis) 110 (1987) 710 – 12.
- 433 D. Y. M. Leung, J. C. Burns, J. W. Newburger, R. S. Geha, J. Clin. Invest. 79 (1987) 468 – 72.
- 434 B. Combe, B. Cosso, J. Clot, M. Bonneau et al., Am. J. Med. 78 (1985) 920 – 8.
- 435 F. C. Breedveld, A. Brand, W. G. van Aken, J. Rheumatol. 12 (1985) 700 – 2.
- 436 E. L. Arsura, A. S. Bick, N. G. Brunner, T. Namba et al., Arch. Intern. Med. 146 (1986) 1365 – 8.
- 437 K. Kawada, P. I. Terasaki, Exp. Hematol (N.Y.) 15 (1987) 133 – 6.
- 438 E. Schuller, A. Govaerts, Eur. Neurol. 22 (1983) 205 – 12.
- 439 A. Salama, C. Mueller-Eckhardt, V. Kiefel, Lancet 2 (1983) 193 – 5.
- 440 R. P. Kimberly, J. E. Salmon, J. B. Bussel, M. K. Crow et al., J. Immunol. 132 (1984) 745 – 50.
- 441 U. Budde et al., Scand. J. Haematol. 37 (1986) 125 – 129.
- 442 A. Etzioni, S. Pollack, A. Benderly, N. Engl. J. Med. 318 (1988) 994.
- 443 G. P. Sandilands, H. I. Atrah, G. Templeton, J. E. Cocker et al., J. Clin. Lab. Immunol. 23 (1987) 109 – 15.
- 444 T. W. Jungi, S. Barandun, Vox Sang. 49 (1985) 9 – 19.
- 445 W. Stohl, Clin. Exp. Immunol. 62 (1985) 200 – 7.
- 446 F. Hashimoto, Y. Sakiyama, S. Matsumoto, Clin. Exp. Immunol. 65 (1986) 409 – 15.
- 447 H. H. Hodes, Pediatrics. 32 (1963) 1 – 3.
- 448 W. B. White, C. R. Desbonnet, M. Ballow, Am. J. Med. 83 (1987) 431 – 4.
- 449 K. Prellner, P. Christensen, O. Kalm, K. Offenbartl, Acta Pathol. Microbiol. Scand. Sect. 94 C (1986) 207 – 11.
- 450 K. K. Christensen, P. Christensen, Pediatric Infectious Diseases 5 (1986) S 189 – 92.
- 451 J. G. Kelton, C. J. Carter, C. Rodger, G. Bebenek et al., Blood 63 (1984) 1434 – 8.
- 452 A. S. Cross, B. M. Alving, J. C. Sadoff, P. Baldwin et al., Lancet 1 (1984) 912.
- 453 M. Berger, P. Rosencranz, C. Y. Brown, Clin. Immunol. Immunopathol. 34 (1985) 227 – 36.
- 454 J. Kulics, E. Rajnavolgyi, G. Fust, J. Gergely, Mol. Immunol. 20 (1983) 805 – 10.
- 455 E. F. Ellis, C. S. Henney, J. Allergy 43 (1969) 45 – 54.
- 456 R. C. Williams, O. J. Mellbye, G. Kronvall, Infect. Immun. 6 (1972) 316 – 23.
- 457
D. S. Feingold,
F. Oski,
Arch. Intern. Med.
116
(1965)
226 – 8.
10.1001/archinte.1965.03870030006002 Google Scholar
- 458 R. C. Millican, J. D. Rust, J. Infect. Dis. 107 (1960) 389 – 394.
- 459 E. Lachman, S. B. Pitsoe, S. L. Gaffin, Lancet 1 (1984) 981 – 3.
- 460 M. A. Thomson, J. S. Afr. Vet. Assoc. 54 (1983) 279 – 81.
- 461 M. L. Forman, R. Stiehm, N. Engl. J. Med. 281 (1969) 926 – 31.
- 462 A. S. Shigeoka, R. T. Hall, H. R. Hill, Lancet 1 (1978) 636 – 8.
- 463 E. J. Ziegler, J. A. McCutchan, J. Fierer, M. P. Glauser et al., N. Engl. J. Med. 307 (1982) 1225 – 30.
- 464 J.-D. Baumgartner, M. P. Glauser, J. A. McCutchan, E. J. Ziegler et al., Lancet 2 (1985) 59 –63.
- 465 T. Calandra, J. Schellekens, J. Verhoef, M. P. Glauser, Program and Abstracts for the 4th International Symposium on Infections in the Immunocompromised Host, Ronneby Brunn, Sweden, 1986. Abstract No. 128.
- 466 A. H. Levy, J. Chronic Dis. 15 (1962) 589 – 98.
- 467 J. Bjorkander, C. Cunningham-Rundles, P. Lundin, R. Olsson et al., Am. J. Med. 84 (1988) 107 – 111.
- 468 R. S. Lane, Lancet 2 (1983) 974 – 5.
- 469 H. D. Ochs, S. H. Fischer, F. S. Virant, M. L. Lee et al., Lancet 1 (1985) 404 – 5.
- 470 C. L. S. Leen, P. L. Yap, G. Neill, D. B. L. McClelland et al., Vox Sang. 50 (1986) 26 – 32.
- 471 B. Cuthbertson, R. J. Perry, P. R. Foster, K. G. Reid, J. Infect. 15 (1987) 125 – 33.
- 472 C. C. Wood, A. E. Williams, J. G. McNamara, J. A. Annunziata et al., Ann. Intern. Med. 105 (1986) 536 – 8.
- 473 Y. Hamamoto, S. Harada, N. Yamamoto, Y. Uemura et al., Vox Sang. 53 (1987) 65 – 9.
- 474 Morb. Mort. Wkly. Rep. 36 (1987) 728 – 9.
- 475 A. W. Burks, H. A. Sampson, R. H. Buckley, N. Engl. J. Med. 314 (1986) 560 – 4.
- 476 R. Apfelzweig, D. Piskiewicz, J. A. Hooper, J. Clin. Immunol. 7 (1987) 46 – 50.
- 477 R. Paganelli, I. Quinti, G. P. D'Offizi, C. Papetti et al., Vox Sang. 51 (1986) 87 – 91.
- 478 J. C. Barton, G. A. Herrera, J. H. Galla, L. F. Bertoli et al., Am. J. Med. 82 (1987) 624 – 9.
- 479 A. G. Brox, D. Cournoyer, M. Sternbach, G. Spurll, Am. J. Med. 82 (1987) 633 – 5.
- 480 R. Schroff, K. Foon, S. Beatty, R. Oldham et al.: “Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy,” Can. Res. 45 (1985) 879 – 885.
- 481 M. Nose, H. Wigzell: “Biological significance of carbohydrate chains on monoclonal antibodies,” Proc. Natl. Acad. Sci. U.S.A. 80 (1983) 6632 – 6636.
- 482 E. Englemann, S. Foung, J. Larrick, A Raubitschek (eds.): Human Hybridomas and Monoclonal Antibodies, Plenum Press, New York 1985.
- 483 A. Strelkelkaus (ed.): Human Hybridomas; Diagnostic and Therapeutic Applications, Marcel Dekker, New York 1986.
- 484 D. Kozbor, J. Roder, T. Chang, Z. Stplewski et al.: “Human antitetanus toxoid monoclonal antibody secreted by EBV-transformed human B cells fused with murine myeloma,” Hybridoma 1 (1982) 323 – 8.
- 485 J. Larrick, K. Truitt, A. Raubitschek, G. Senyk et al., “Characterization of human hybridomas secreting antibody in tetanus toxoid,” Proc. Natl. Acad. Sci. U.S.A. 80 (1983) 6376 – 6380.
- 486 N. Chiorazzi, R. Wasserman, H. Kunkel: “Use of Epstein-Barr virus-transformed B cell lines for the generation of immunoglobulin-producing human B cell hybridomas,” J. Exp. Med. 156 (1982) 930 – 935.
- 487 F. Gigliotti, R. Insel: “Protective human hybridoma antibody to tetanus toxin,” J. Clin. Invest. 70 (1982) 1306 – 1309.
- 488 L. Olsson, T. Mazauric, J. Vincent-Falquet, J. Armand: “A human monoclonal antibody specific for tetanus toxoid,” Dev. Biol. Stand. 57 (1984) 87 – 91.
- 489 S. Tsuchiya, S. Yokoyama, O. Yoshie, Y. Ono: “Production fo diphtheria antitoxin antibody in Epstein-Barr virus induced lymphoblastoid cell lines.” J. Immunol. 124 (1980) 1970 – 1976.
- 490 E. Ziegler, J. McCutchan, J. Fierer et al.: “Treatment of Gram-negative bacteremia and shock with human anti-serum to a mutant Escherichia coli,” N. Engl. J. Med. 307 (1982) 1225 – 1230.
- 491
W. Bogard,
E. Hornberger,
P. Kung in
E. Englemann,
S. Foung,
J. Larrick,
A. Raubitscheck (eds.):
Production and characterization of human monoclonal antibodies against Gram-negative bacteria,
Human Hybridomas and Monoclonal Antibodies,
Plenum Press,
New York
1985,
pp. 95 – 112.
10.1007/978-1-4684-4949-5_6 Google Scholar
- 492 N. Teng, H. Kaplan, J. Hebert et al.: “Protection against Gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies,” Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 179 – 184.
- 493 J. Larrick, M. Jahnsen, G. Senyk, S. Weiss et al. in H. Friedman (ed.): Production of human monoclonal antibodies recognizing cross-reactive determinants on lipopolysaccharides,” The Immunology and Immunopharmacology of Endotoxins, 1986, pp. 75 – 81.
- 494 M. Pollack, A. Raubitschek, J. Larrick: “Cross-reactive human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region of endotoxin,” J. Clin. Invest. 79 (1987) 1421 – 1430.
- 495 J. Baumgartner, M. Glauser, J. McCutchan, E. Zeigler et al.: “Prevention of gramnegative shock and death in surgical patients by antibody to endotoxin core glycolipid.” Lancet 2 (1985) 59 – 63.
- 496 J. Larrick, S. Hart, D. Lippman, M. Glembourtt et al. in A. Strelkelkaus (ed.): Generation and characterization of human monoclonal anti-Pseudomonas aeruginosa antibodies, Human Hybridomas; Diagnostic and Therapeutic Applications, Marcel Dekker, New York 1986, pp. 65 – 80.
- 497
J. Larrick,
B. Dyer,
G. Senyk et al. in
E. Engleman,
S. Foung,
J. Larrick,
A. Raubitschek (eds.):
In vitro expression of human B cells for the production of human monoclonal antibodies,
Human Hybridomas and Monoclonal Antibodies,
Plenum Press,
New York
1985,
pp. 149 – 165.
10.1007/978-1-4684-4949-5_9 Google Scholar
- 498 K. Hunter, Jr., G. Fischer, V. Hemming, S. Wilson et al.: “Antibacterial activity of a human monoclonal antibody to Haemophilus influenzae type B capsular polysaccharide,” Lancet 2 (1982) 789 – 799.
- 499 H. Peltola, H. Kayhty, M. Virtanen, P. Makela: “Prevention of Hemophilus influenza type b bacteremic infections with the capsular polysaccharide vaccine,” N. Engl. J. Med. 310 (1984) 1561 –1565.
- 500 T. Atlaw, D. Kozbor, J. Roder: “Human monoclonal antibodies against Mycobacterium Leprae,” Infect. Immun. 49 (1985) 104 – 110.
- 501 B. Brodeur, L. Lagace, Y. Larose, M. Martin et al. in B. Schook (ed.): Mouse-human myeloma partner for the production of heterohybridomas, Monoclonal Antibodies , Marcel Dekker, 1986, p. 51.
- 502 M. Steinitz, S. Tamir, A. Goldfarb: “Human anti-pneumococci antibody produced by an Epstein-Barr virus (EBV)-immortalized cell line,” J. Immunol. 132 (1984) 877 – 882.
- 503 J. Schwaber, M. Posner, S. Schlossman, H. Lazarus: “Human-human hybrids secreting pneumococcal antibodies,” Hum. Immunol. 9 (1984) 137 – 142.
- 504 D. Emanuel, J. Gold, J. Colacino, C. Lopez et al.: “A human monoclonal antibody to cytomegalovirus (CMV),” J. Immunol. 133 (1984) 2202 – 2205.
- 505 C. Amadei, S. Michelson, J. Frot, M. Fruchart et al.: “Human anticytomegalovirus (CMV) immunoglobulins secreted by EBV-transformed B-lymphocytes cell lines,” Dev. Biol. Stand. 57 (1984) 283 – 286.
- 506
K. Burnett,
J. Leung,
J. Marinis in
E. Engleman,
S. Foung,
J. Larrick,
A. Raubitschek (eds.):
Human monoclonal antibodies to defined antigens,
Human Hybridomas and Monoclonal Antibodies,
Plenum Press,
New York
1985,
pp. 113 – 133.
10.1007/978-1-4684-4949-5_7 Google Scholar
- 507 Y. Ichimori, K. Sasano, H. Itoh, S. Hitosumachi et al.: “Establishment of hybridomas secreting human monoclonal antibodies against tetanus toxin and hepatitis B virus surface antigen,” Biochem. Biophys. Res. Commun. 129 (1985) 26 – 38.
- 508 E. Stricker, R. Tiebout, P. Lelie, W. Zeijlemaker: “A human monoclonal IgG antihepatitis B surface antibody; production, properties and applications,” Scand. J. Immunol. 22 (1985) 337 – 345.
- 509 R. Beasley et al.: “Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state,” Lancet 2 (1981) 388 – 393.
- 510
S. Foung
et al.:
“Human monoclonal antibodies neutralizing Varicella Zoster virus,”
J. Infect. Dis.
52
(1985)
280 – 285.
10.1093/infdis/152.2.280 Google Scholar
- 511 L. Evans, J. Homsy, W. Morrow, I. Gaston et al.: “Human monoclonal antibody directed against gag gene products of the human immunodeficiency virus,” J. Immunol. 140 (1988) 941 – 943.
- 512 B. Banapour et al.: “Characterization and epitope mapping of a human monoclonal antibody reactive with the envelope glycoprotein of human immunodeficiency virus,” J. Immunol. 138 (1987) 4027 – 33.
- 513 A. Rosen, K. Persson, G. Klein: “Human monoclonal antibodies to a genus-specific chlamydial antigen, produced by EBV-transformed B cells,” J. Immunol. 130 (1983) 2899 – 2902.
- 514 S. Koizumi, S. Fujiwara, H. Kikuta et al.: “Production of human monoclonal antibodies against Epstein-Barr virus specific antigens by the virus immortalized lymphoblastoid cell lines,” Virology 150 (1986) 161 – 170.
- 515 J. Seigneurin et al.: “Herpes simplex virus glycoprotein D; human monoclonal antibody produced by bone marrow cell line,” Science 221 (1983) 173 – 175.
- 516 Y. Masuho et al.: “Generation of hybridomas producing human monoclonal antibodies against herpes simplex virus after in vitro stimulation,” Biochem. Biophys. Res. Commun. 135 (1986) 495 – 505.
- 517 L. Evans, C. Maragos, J. May: “Human lymphoblastoid cell lines established from peripheral blood lymphocytes secreting immunoglobulins directed against herpes simplex virus,” Immunol. Lett. 8 (1984) 39 – 50.
- 518 S. Matsushita, M. Robert-Gurhoff, J. Trepel, J. Cossman et al.: “Human monoclonal antibodies directed against an envelope glycoprotein of human T-cell leukemia virus type 1,” Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 2672 – 2677.
- 519 C. Croce, A. Linnenbach, W. Hall, Z. Steplewski et al.: Production of human hybridomas secreting antibodies to measles virus, Nature (London) 288 (1980) 488 – 489.
- 520 R. Ritts, Jr., A. Ruiz-Arguelles, K. Weyl et al.: “Establishment and characterization of a human non-secreting plasmacytoid cell line and its hybridization with human B cells,” Int. J. Cancer 31 (1983) 133 – 151.
- 521 J. Hilfenhaus, E. Kanzy, R. Kohler, W. Willems: “Generation of human anti-rubella monoclonal antibodies from human hybridomas constructed with antigen-specific Epstein-Barr virus transformed cell lines,” Behring Inst. Mitt. 80 (1986) 31 – 40.
- 522 F. van Meel, P. Steenbakkers, J. Oomen: “Human and chimpanzee monoclonal antibodies,” J. Immunol. Methods 80 (1985) 267 – 280.
- 523 D. Crawford et al.: “Production of human monoclonal antibody to X 31 influenze virus nucleoprotein,” J. Gen. Virol. 64 (1983) 697 – 700.
- 524 R. Schmidt-Ullrich, J. Brown, R. Whittle, P. Lin: “Human-human hybridomas secreting monoclonal antibodies to the M.W. 195 000 Plasmodium falciparum blood stage antigen,” J. Exp. Med. 163 (1986) 179 – 189.
- 525 R. Udomsangpetch et al.: “Human monoclonal antibodies to Pf-155, a major antigen of malaria parasite Plasmodium falciparum,” Science 231 (1986) 55 – 59.
Further Reading
-
Z. Guo,
G.-J. Boons (eds.):
Carbohydrate-based Vaccines and Immunotherapies,
John Wiley & Sons,
Hoboken, NJ
2009.
10.1002/9780470473283 Google Scholar
- M. Little (ed.): Recombinant Antibodies for Immunotherapy, Cambridge University Press, New York 2009.
-
R. Orentas,
J. W. Hodge,
B. D. Johnson:
Cancer Vaccines and Tumor Immunity,
Wiley-Interscience,
Hoboken, NJ
2008.
10.1002/9780470170113 Google Scholar
- G. C. Prendergast, E. M. Jaffee (eds.): Cancer Immunotherapy, Academic Press, Amsterdam 2007.
-
V. E. J. C. Schijns,
D. T. O'Hagan (eds.):
Immunopotentiators in Modern Vaccines,
Academic Press,
Boston
2006.
10.1016/B978-012088403-2/50002-2 Google Scholar
- M. Schleef (ed.): DNA Pharmaceuticals, Wiley-VCH, Weinheim 2005.
-
M. Singh (ed.):
Vaccine Adjuvants and Delivery Systems,
Wiley-Interscience,
Hoboken, NJ
2007.
10.1002/9780470134931 Google Scholar
-
G. Somasekhar,
S. Chao:
Vaccine Technology,
Kirk Othmer Encyclopedia of Chemical Technology,
5th edition,
John Wiley & Sons,
Hoboken, NJ,
online DOI: 10.1002/0471238961.2201030308190905.a01.pub2.
10.1002/0471238961.2201030308190905.a01.pub2 Google Scholar
- S. K. Tyring (ed.): Antiviral Agents, Vaccines, and Immunotherapies, Marcel Dekker, New York 2005.
-
S. Wong:
Immunotherapeutic Agents,
Kirk Othmer Encyclopedia of Chemical Technology,
5th edition,
John Wiley & Sons,
Hoboken, NJ,
online DOI: 10.1002/0471238961.0913132123151407.a01.
10.1002/0471238961.0913132123151407.a01 Google Scholar
